3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Completed
4
Recruiting
3
Withdrawn
1
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
CNS
1
Conditions
Breast Neoplasms
3
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Fulvestrant
58
Trastuzumab
49
Capecitabine
47
Letrozole
45
pembrolizumab
41
Carboplatin
41
Paclitaxel
39
Cyclophosphamide
38
ribociclib
37
pertuzumab
36
abemaciclib
36
Blood Specimen Collection
31
trastuzumab deruxtecan
27
Specimen Handling
27
Docetaxel
27
Surveys and Questionnaires
26
Anastrozole
25
exemestane
24
Tamoxifen
24
palbociclib
21
130-nm albumin-bound paclitaxel
21
Magnetic Resonance Spectroscopy
19
sacituzumab govitecan
18
eribulin
18
Radiotherapy
18
Gemcitabine
18
Biopsy
18
olaparib
17
Injections
17
Epirubicin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Breast Neoplasms
×
RAD1901
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled
NCT07198724
2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2
Recruiting
65 enrolled
NCT07222215
2026-01-22
CAPELA
Dana-Farber Cancer Institute
Phase 2
Recruiting
297 enrolled